APA (7th ed.) Citation

S, Z., X, X., J, C., C, S., Y, H., X, W., . . . S, W. (2026). CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients. Clinical laboratory, 72(5), . https://doi.org/10.7754/Clin.Lab.2025.250744

Chicago Style (17th ed.) Citation

S, Zhou, Xu X, Cuo J, Sun C, Hou Y, Wang X, Nana D, and Weixun S. "CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients." Clinical Laboratory 72, no. 5 (2026). https://doi.org/10.7754/Clin.Lab.2025.250744.

MLA (9th ed.) Citation

S, Zhou, et al. "CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients." Clinical Laboratory, vol. 72, no. 5, 2026, https://doi.org/10.7754/Clin.Lab.2025.250744.